Sagent Pharmaceuticals, a specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, has launched Adenosine injection, USP, a pharmacologic stress agent, in two preservative- free vial presentations.

According to IMS, for the 12 months ending January 2014, the US market for Adenosine injection, USP approximated $43 million. As with all products in Sagent's portfolio, Adenosine features the company's PreventIV MeasuresSM packaging and labelling, designed to help reduce medication errors.

"We are pleased to be working with our joint venture partner, Agila, a Mylan company, to support the launch of Adenosine at market formation," said Jeffrey.M Yordon, chief executive officer and chairman of the Board of Sagent.

Adenosine injection, USP is indicated as an adjunct to thallium-201 myocardial perfusion scintigraphy in patients unable to exercise adequately.